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Chronic pancreatitis (CP) is a debilitating disease that can result in chronic abdominal pain, malnutrition, and other 
related complications. The main aims of treatment are to control symptoms, prevent disease progression, and correct any 
complications. A multidisciplinary approach involving medical, endoscopic, and surgical therapy is important. Endoscopic 
therapy plays a specific role in carefully selected patients as primary interventional therapy when medical measures fail 
or in patients who are not suitable for surgery. Endoscopic therapy is also used as a bridge to surgery or as a means to 
assess the potential response to pancreatic surgery. This review addresses the role of endoscopic therapy in relief of 
obstruction of the pancreatic duct (PD) and bile du ct, closure of PD leaks, and drainage of pseudocysts in CP. The role of 
endoscopic ultrasound-guided celiac plexus block for pain in chronic pancreatitis is also discussed.
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INTRODUCTION
Chronic pancreatitis (CP) is a continuous inflammatory 
disease of the pancreas characterized by irreversible mor-
phological changes that typically cause pain and/or per-
manent loss of function [1]. Patients with chronic pancre-
atitis are also at risk for developing pancreatic cancer. The 
aim of endoscopic therapy is to control symptoms, prevent 
progression of the disease, and correct complications.
Pain is one of the main symptoms of chronic pancreati-
tis, and its etiology is multifactorial. Pain can result from 
increased pressure in the main pancreatic duct (PD) lead-
ing to intraparenchymal/interstitial hypertension or from 
peripancreatic/celiac neural inflammation [2,3]. Intra-
ductal hypertension occurs primarily due to obstruction 
of pancreatic juice outflow from PD strictures, intraductal 
stones, decreased compliance of the main PD, and major/
minor papillary sphincter stenosis [4]. Other factors that 
may indirectly contribute to pain include the complica-
tions of CP, such as pseudocysts, PD leaks/ascites, and bili-
ary and duodenal obstruction.
The role of endoscopic therapy in CP to alleviate pain by 
reducing outflow obstruction of the PD and by decreas-
ing ductal hypertension has recently become the subject 
of debate. Two studies comparing endoscopic therapy to 
surgery have shown that surgical outcomes for pain re-
lief were more durable [5,6]. However, the subjectivity of 
pain assessment, lack of blinding, and small sample size 
in these studies may have led to bias. Additionally, the 
specific disease characteristics, such as the presence of 
multiple pancreatic stones and the locations of the stric-
tures, were not clearly described in the surgical group, 
which suggests there was a possibility of chance random-
ization of more refractory patients to the endoscopy treat-
ment group. Hence, some authors [7] have suggested that 
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selected patients as primary interventional therapy when 
medical measures fail or in high-risk surgical candidates. 
Endotherapy for CP is also utilized as a bridge to surgery 
or as a means to assess potential response to pancreatic 
surgery [8]. Finally, endotherapy is employed selectively 
by the authors for treatment of recurrent abdominal pain 
or complications after pancreatic surgery for CP. Other 
endoscopic therapies to relieve pain include the use of en-
doscopic ultrasound (EUS) to provide EUS-guided celiac 
block for CP.
The role of endotherapy in improving pancreatic func-
tion is less clear, with a large multicenter study [9] show-
ing no improvement in pancreatic function. However, one 
secretin-enhanced magnetic resonance cholangiopan-
creatography study suggested that pancreatic exocrine 
function can improve after endoscopic therapy [10], and 
another study showed that the development of clinical ste-
atorrhea was delayed for about 10 years when compared 
with the natural history of chronic pancreatitis [11].
PANCREATIC ENDOTHERAPY
The principle of pancreatic endotherapy is to allevi-
ate the outflow obstruction to exocrine juice flow. This is 
based on the assumption that PD hypertension is the cause 
of the symptoms. Failure to respond to endoscopic therapy 
suggests that PD hypertension is not the primary cause 
of the patient’s symptoms or that the intraductal pressure 
was not adequately reduced to achieve clinical benefit.
Main PD deep cannulation is the first crucial step to suc-
cessful pancreatic endotherapy. With the endoscope in the 
short position and the papilla viewed en face, the main PD 
can be accessed with a regular cannula at the 1-4 o’clock 
position of the native major papilla orifice and at the 5 
o’clock position of the papilla with prior biliary sphincter-
otomy. If minor papilla cannulation is indicated, it is typi-
cally achieved with the endoscope in the long position us-
ing a highly tapered catheter with a 0.46 mm and 0.53 mm 
guide wire. Secretin administration to promote pancreatic 
juice flow and/or methylene blue flushes over the papilla 
may help in orifice identification and cannulation [12,13]. 
In cases where cannulation is not achieved despite the use 
of the above described methods, EUS-guided pancrea-
tography has been described for both identification of the 
desired papillary orifice and successful PD drainage [14-
16]. In failed main PD deep cannulation due to obstruction 
or extreme tortuosity of the ventral duct, access to the 
main PD may be obtained via the minor papilla when the 
minor papilla and accessory duct are patent. Once deep 
cannulation is acquired with placement of wires, specific 
endotherapy can be performed as detailed below.
PANCREATIC DUCT STRUCTURES
PD strictures are typically benign and occur secondary 
to previous stone disease, inflammation, or fibrosis [17]. 
However, a retrospective series of 355 patients reported 
a 12% risk of malignancy in isolated PD strictures [18]. 
It is therefore crucial to have a high index of suspicion 
for malignancy in patients with PD strictures and obtain 
pancreatic imaging with dual-phase computed tomogra-
phy (CT) scan and/or EUS prior to endoscopic retrograde 
cholangiopancreatography (ERCP). Tissue sampling of the 
stricture during ERCP should also be performed on the PD 
stricture in patients without risk factors for CP, symptoms 
such as weight loss and anorexia, or evidence of CP on 
pancreatography. Factors affecting success of endotherapy 
include location, the number and length of the strictures, 
and the presence of upstream dilation. PD strictures in 
the tail of the pancreas and multiple strictures along the 
length of the main PD are more difficult to manage by en-
dotherapy. The best outcomes of endotherapy are achieved 
when strictures of the main PD in the head with upstream 
dilation are stented.
Technique of endotherapy
Pancreatic sphincterotomy (major and/or minor papilla) 
is frequently performed after cannulation and wire place-
ment across the stricture. Stricture dilation is performed 
with a graduated dilating catheter or balloon dilators. One 
or more PD stents are advanced over the guide wire using 
a pusher tube. The choice of stent size is dependent on the 
size of the PD downstream of the stricture. Smaller ducts 
require 3-7 French stents, whereas more dilated PDs re-
quire 8.5-11.5 French stents. We prefer placing stents with 
an external pigtail and an internal flange to prevent proxi-
mal and distal migration, respectively. Occasionally, PD 
strictures are too tight or too angulated to allow passage of 
conventional dilators or catheters, and Familiari et al. [19] 
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tor) across these strictures for 24 hours. The mechanism 
of action is thought to be the presence of the guide wire 
across the stricture in combination with slight movements 
caused by breathing resulting in dilation of the stricture. 
Subsequent dilation and placement of a stent was success-
ful. The timing of pancreatic stent exchange is variable. 
Farnbacher et al. [20] attempted to predict factors that 
resulted in clogging of PD stents. However, clinical and 
laboratory data did not reliably indicate clogging, and 
therefore stent exchange or removal was recommended 
within 3 months in high-risk patients. Delhaye et al. [21] 
showed that on-demand exchange was as effective as early 
replacement based on the theory that pancreatic juices can 
drain around the stent even when it is occluded. Currently, 
routine (6-12 weeks) and on-demand exchange based on 
recurrence of symptoms are used in clinical practice.
Results of endotherapy
Wilcox [22] summarized the results of PD stent place-
ment for pain in chronic pancreatitis among 1500 patients 
treated in 15 series. Benefit was seen in 31-100% during 
a follow-up interval of 8-72 months. The greatest benefit 
was seen in patients with dominant strictures and dilated 
ducts [23,24]. In a recent review of nine series including a 
total of 491 patients undergoing stenting (5-11.5 Fr stents) 
for strictures, Nguyen-Tang and Dumonceau [25] reported 
early pain relief in 65-95% and sustained pain relief in 
52-90% of cases. Patients were followed up over 14-69 
months, and 4-26% of patients subsequently underwent 
operations after endotherapy. As with surgical decompres-
sive procedures, it appears that the response to stenting is 
attenuated over time.
In a large multicenter study, 1,018 patients with CP [9]
were followed prospectively for a mean of 4.9 years after 
endoscopic intervention. The study population included 
478 patients with strictures alone. The remaining patients 
had stones alone or strictures with stones. All patients 
with strictures alone had pain initially, and 37% still had 
pain at follow-up. A significant reduction in pain (no or 
weak pain) was achieved in 84% of cases. Rates of pain 
relief were similar in patients with dominant strictures in 
the head and/or body, pancreatic stones in the head and/or 
body, a combination of stones and strictures, and complex 
pathology. It appears that complete stricture resolution is 
not mandatory for symptom improvement, which implies 
that luminal patency was sufficient or that other therapies 
performed along with stenting contributed to the benefit. 
In all of these studies, single plastic stents were usually 
sequentially changed at multiple ERCP sessions.
In terms of pain relief, the long-term efficacy of pan-
creatic stenting is uncertain, and multiple ERCPs are 
required for stent exchanges either at regular intervals 
or “on-demand” (i.e., when pain develops). Even with an 
on-demand schedule, the number of ERCP sessions ap-
proximates four or five in large studies [26,27], making 
this strategy relatively unsatisfactory. Costamagna et al. 
[28] attempted to address this issue by placing multiple 
pancreatic stents. Nineteen patients with dominant PD 
strictures in the pancreatic head who had pain relief by 
a single previously placed PD stent underwent balloon 
dilation of the stricture and placement of 8.5-10 French 
pancreatic stents 4-7 cm in length (median of three stents; 
range, 2 to 4 based on the tightness of the stricture) for 
6-12 months. Stricture resolution was seen in 95% of pa-
tients at stent removal. After a median follow-up period of 
38 months after stent removal, 84% remained pain-free, 
and PD stricture recurred in 10.5% of cases (two patients) 
and was subsequently treated with single stent placement. 
The main advantage of this technique was the low number 
of ERCP sessions (two) and large dilation diameter due 
to the multiple stents placed, which may account for the 
higher success rate. However, prospective controlled stud-
ies are required to confirm these findings. To date, there 
have been no trials comparing single vs. multiple stenting 
for PD strictures.
Attempts to reduce the number of procedures and im-
prove the outcome of stenting with self-expandable metal 
stents (SEMS) have met with varying success. An early 
study by Eisendrath and Deviere [29] evaluated a partially 
covered SEMS for PD stricture. Unfortunately, after 6 
months of treatment in 29 patients with 18 Fr metal stents 
23 mm in length, most patients developed stent occlusion 
due to mucosal hyperplasia. Fully covered SEMS have 
recently become available and were thought to overcome 
the problem of mucosal hyperplasia. Sauer et al. [30] used 
a Viabil stent 8 mm in diameter (Conmed, Utica, NY, 
USA) in six patients who had persistent pain after plastic 
stenting of an MPD stricture. One patient had pancreatic 
cancer and was excluded from the study. Three of the 
remaining five patients who underwent stent removal 
at 3 months presented with early symptomatic stricture 
recurrence. Park et al. [31] used another model of fully Tan Dmy and sherman s. Endoscopic therapy in chronic pancreatitis     387
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covered SEMS (Niti D-type, Taewoong, Seoul, Korea) in 
13 patients with recurrent pain and refractory MPD stric-
ture after removal of pancreatic plastic stents. The stents 
were removed 2 months after insertion. SEMS migration 
was observed in five (38%) of 13 patients (including one 
case of proximal migration). Complications developed in 
five (30%) patients, including cholestasis and pancreatitis 
flares. During a median follow-up of 5 months after SEMS 
removal, no pain relapse was reported. The same group 
of authors recently published a larger study of 32 patients 
[32] using a modified version of the original stent, and all 
patients achieved pain relief from stent placement. There 
was no occurrence of stent-induced pancreatitis or pan-
creatic sepsis. None of the stents migrated, and all stents 
were easily removed. Follow-up ERCP 3 months after 
stent placement showed resolution of duct strictures in all 
patients. Pancreatograms obtained at fully covered SEMS 
removal displayed de novo focal pancreatic duct strictures 
in five patients, but all were asymptomatic. Although these 
studies are encouraging, further refinement in SEMS de-
sign and additional long-term data are needed.
Some natural history studies of CP [33,34] have shown 
spontaneous pain relief in late stages due to pancreatic 
“burn out.” However, Lankisch et al. [35] showed that 
even after 10 years of follow-up of severe pancreatitis, 
more than 50% of patients continued to have pain. This 
variation in natural history can bias the results of outcome 
studies of endotherapy for pancreatic strictures due to lack 
of sham control procedure. Wilcox and Lopes [36] recently 
proposed a much-awaited trial studying pain and psycho-
social outcomes in patients with symptomatic PD stric-
tures who were randomized to pancreatic endotherapy or 
sham procedure. If less than 50% improvement in pain in 
patients randomized to sham procedure is observed, there 
will be crossover to the endoscopic intervention group, and 
otherwise they will be followed clinically for the proposed 
duration of 3 years. The results of this study are eagerly 
awaited.
PANCREATIC DUCT STONES
The prevalence of stones in CP ranges from 20 to 60% 
[9,37]. The majority of pancreatic stones are radioopaque 
due to calcium content, with a small percentage being 
radiolucent. Obstruction of the PD from stones with resul-
tant ductal hypertension is thought to be one of the poten-
tial mechanisms responsible for attacks of acute pancreati-
tis or exacerbations of chronic abdominal pain in patients 
with CP. This suggestion is supported by studies showing 
that removal of stones using various methods results in 
symptomatic improvement.
Technique of endotherapy
Small pancreatic stones can be removed after pancreatic 
(major/minor) sphincterotomy (Fig. 1) using balloon or 
basket extraction. Using these standard techniques, the 
reported rate of success is approximately 50-75% [38]. 
However, if there is a stricture downstream (toward the 
duodenum) of the stone, it is usually necessary to dilate 
the stricture prior to attempting stone extraction. Sher-
man et al. [39] found that the following factors favored 
complete stone removal by endoscopic techniques alone: 
stones < 1 cm in size; presence of three or fewer stones; 
stones confined to the head and body; and absence of 
impacted stones or stones upstream (toward the tail) of a 
stricture. Stones that are larger, impacted, or upstream to 
a stricture frequently require fragmentation via mechani-
cal lithotripsy, intraductal lithotripsy with a pulsed dye la-
ser or electrohydraulic lithotripsy (EHL), or extracorporeal 
shockwave lithotripsy (ESWL) prior to attempted extrac-
tion. Among the three options for fragmentation, ESWL 
is the most utilized method, although there have been no 
comparative trials among different forms of lithotripsy.
The success rate of stone fragmentation with ESWL is 
usually > 90% [40], and it can be performed under moder-
ate sedation or general anesthesia. Some authors recom-
mend the use of general anesthesia, as pancreatic ESWL 
can be very painful. In some cases, general anesthesia can 
be used to assist ESWL in small stones that are difficult to 
target by limiting respiratory movements with decreased 
tidal volume [25]. Localization of the stones is done under 
ultrasound or fluoroscopy. However, previous studies have 
shown that ultrasound localization of pancreatic stones 
results in lower fragmentation rates [37,40]. Following 
ESWL, endoscopic removal of the stone fragments is per-
formed in the same manner as for small stones, during the 
same or in a different session (based on the availability of 
a local lithotripter and personnel). ESWL alone without 
the need for ERCP has been shown in large uncontrolled 
series [41,42] to relieve pain in calcifying CP. This was con-
firmed in a large prospective randomized controlled trial, 388    The Korean Journal of Internal medicine Vol. 26, No. 4, December 2011
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which showed spontaneous passage of stone fragments 
after ESWL without the need for endoscopic removal [43].
Large radiolucent pancreatic stones that cannot be tar-
geted by fluoroscopy for ESWL can be removed via me-
chanical lithotripsy or intraductal lithotripsy with pulsed 
dye laser or EHL. Mechanical lithotripsy requires stone 
capture in a basket, which may be difficult for impacted 
stones. Mechanical lithotripsy has been reported to have 
a three times greater complication rate when performed 
in the PD compared with in the bile duct [38]. Intraductal 
lithotripsy requires a specialized mother-daughter scope 
system or single-operator system (Spyglass system, Boston 
Scientific, Natick, MA, USA) to allow for direct duct visu-
alization. There is limited discussion of these techniques 
Figure 1. Pancreatic duct stone removal. (A) Pancreatic duct stone at minor papilla. (B) Needle knife sphincterotomy over stone. (C) Pas-
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in the literature. Using the mother-daughter scope system, 
Howell et al. [44] reported complete stone fragmentation 
using EHL in 3 of 6 patients, and the interim multination-
al registry of the Spyglass system [45] reported successful 
EHL of pancreatic stones in eight of 10 attempted cases 
(EHL was not attempted in some cases due to difficulties 
in placing the EHL probe in contact with the stone). Based 
on limited experience and technical limitations, these 
techniques are considered second line and are used when 
ESWL fails to fragment obstructive PD stones.
Results
The technical success of endoscopic removal of pan-
creatic stones depends on the size, number, and location 
of the stones [9], the presence of a ductal stricture, and 
whether the stone is impacted. In a series by Sherman and 
colleagues [39], using endoscopic techniques alone, 72% of 
cases had complete or partial stone removal, and 68% had 
symptomatic improvement. Symptomatic improvement 
was most evident in the group of patients with chronic 
relapsing pancreatitis (vs. those presenting with chronic 
continuous pain alone; 83% vs. 46%, respectively). When 
ESWL is combined with endoscopic therapy, the success of 
stone clearance and longer-term symptomatic relief were 
improved [37,40,46-49].
A meta-analysis [50] of 16 studies that included 588 
patients showed that ESWL combined with pancreatic en-
dotherapy had a significant impact on reducing pancreatic 
stone burden and reducing pain. A recent review showed 
that ESWL and endotherapy resulted in pain relief in 54-
90% of patients over a follow-up of 7-173 months [24]. Du-
monceau et al. [43] compared ESWL alone vs. ESWL and 
endotherapy; pain relapse at the end of a 2-year period 
was not significantly different between the two (ESWL 
alone, 38%; ESWL with endotherapy, 45%). The cost of 
ESWL alone was one-third that of ESWL with endother-
apy. Patient selection with refractory disease may partly 
explain the much higher rates of pain relapse in  this study 
compared with previous studies. On an intention-to-treat 
analysis, this study also demonstrated that the median de-
lay between the onset of CP and persistent pain relief was 
1.1 years in the treated (ESWL alone or combined therapy) 
group (n = 55) compared with 4 years in the untreated ref-
erence cohort (n = 42) (p < 0.001). We feel that it is helpful 
to remove PD stones in symptomatic patients when the 
stones are located in the main duct (in the head and/or 
body), which is more readily accessible. Ancillary ESWL 
will be required for more difficult stones.
PANCREATIC DUCT LEAKS/FISTULAE
PD leaks in patients with CP can occur from an up-
stream blowout of obstructing strictures or stones in 
chronic pancreatitis [51-53]. They can manifest as pan-
creatic ascites, internal fistulae (e.g., pseudocysts, pleural 
effusion to other organs), or external cutaneous fistulae. 
Leaks may arise from the main duct or side branches. If 
the leak arises from the main duct, the duct may be par-
tially disrupted, in which case the duct retains continuity 
(Fig. 2A and 2B) or completely disrupted, where there is 
a disconnection between the upstream and downstream 
main duct. On the pancreatogram, the PD leak/disruption 
is seen as extravasation of the contrast outside the ductal 
structure or quick disappearance of contrast from the duct 
at the sites of leaks without clearance of contrast in the 
downstream duct (toward the head of the pancreas). When 
an abrupt cutoff of the PD is seen in a patient with clinical 
suspicion of a pancreatic leak, a disconnected duct (also 
known as disconnected duct syndrome or disconnected 
pancreatic tail) is likely, in which case viable pancreatic 
tissue is seen upstream on cross-sectional imaging. Di-
verting the pancreatic juice flow away from the fistulae 
and if possible bridging the pancreatic leak with transpap-
illary stents can successfully treat the fistulae (Fig. 2C and 
2D).
Results
Telford et al. [54] showed that 58% (25 of 43 patients) of 
pancreatic leaks resolved with pancreatic stenting with no 
recurrence during a 2-year follow-up period. Varadarajulu 
et al. [55] showed a success rate of 56% (52 of 92 patients) 
with multivariate analysis and showed that a partially dis-
rupted duct and a stent bridging the disruption were asso-
ciated with a successful outcome for pancreatic stenting.
Endoscopic injection of fibrin glue into the fistulous 
tract as an adjunct to the standard endoscopic treatment 
resulted in resolution of 66% of fistulae (8/12) at a median 
follow-up of 20.7 months [56]. However, this technique is 
not routinely utilized.
Complete disruption of the PD is less amenable to endo-
scopic therapy. In a report of 22 patients [57] with discon-390    The Korean Journal of Internal medicine Vol. 26, No. 4, December 2011
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nected pancreatic tail syndrome treated endoscopically, 13 
(59%) had either no initial response or recurrence of pan-
creatic leak. Although all patients in this series had acute 
necrotizing pancreatitis, about half had underlying CP. 
Endoscopic treatment of the disconnected PD syndrome is 
complex because the upstream-disconnected segment of 
the pancreas still secretes and has no communication with 
the duodenum. As long as this part of the pancreas re-
mains viable, any “temporary” therapy will lead to a high 
recurrence rate. Thus, one endoscopic option is to drain 
the collection associated with the leak with transmural 
stents placed “permanently” or until the upstream pancre-
as becomes atrophic and therefore no longer secretes. To 
date, there have been no comparative studies of surgical, 
medical, and endoscopic therapy for the treatment of PD 
leaks.
Figure 2. Treatment of pancreatic duct leak. (A) Leak seen from ventral duct. (B) Filling of main duct upstream of the leak. (C) Crossing 
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PANCREATIC PSEUDOCYST
Pseudocysts are encapsulated collections of pancreatic 
juice, pure and/or containing inflammatory/necrotic de-
bris, which are situated either outside or within the limits 
of the pancreas from which they arise. They complicate the 
course of CP in 20-40% of patients, and spontaneous reso-
lution occurs in < 10% of cases, mostly for collections < 3 
cm in diameter [58,59]. In CP, pseudocysts can occur as a 
result of rupture of a side branch or the main PD itself due 
to PD hypertension, or they may occur as a consequence of 
the ongoing inflammatory process. Although many pseu-
docysts fail to resolve spontaneously, not all require drain-
age. The American Society of Gastrointestinal Endoscopy   
recommends that pseudocyst drainage should be consid-
ered for 1) symptomatic lesions (abdominal pain, gastric 
outlet obstruction, early satiety, weight loss, or jaundice), 
2) infected cysts, or 3) enlarging cysts [60]. If a collection 
develops due to an episode of acute-on-chronic pancre-
atitis, endoscopic drainage is usually considered after a 
minimum of 4-6 weeks to allow liquefaction of necrosis 
(thick debris does not drain well through small-diameter 
endoscopic stents) and for a formed wall to develop [61]. 
If drainage cannot be delayed due to sepsis, surgical de-
bridement (or in selected cases, endoscopic necrosectomy 
with abundant lavage) is recommended [62]. Optimal 
management of a pseudocyst requires a multidisciplinary 
approach with input from surgery, gastroenterology, and 
interventional radiology. The technical and long-term 
success of endoscopic pseudocyst drainage increase for a 
single-compartment cyst with a mature wall and absence 
of necrosis.
Selection of the route (transpapillary vs. transmural) 
of endoscopic drainage depends on the presence of com-
munication between the pseudocyst and pancreatic ductal 
system and on the size of the cyst. This information can be 
ascertained from any combination of imaging with EUS, 
magnetic resonance cholangiopancreatography (MRCP) 
with secretin stimulation, or ERP. Endoscopic transmural 
drainage is chosen if the cyst is not communicating with 
the duct, whereas the transpapillary route is preferred if 
there is communication with PD and the cyst size is rela-
tively small (usually < 5-6 cm). If the communicating pseu-
docyst is particularly large, combined transpapillary and 
transmural drainage can be performed. Transpapillary 
drainage usually requires a pancreatic sphincterotomy 
prior to placement of the pancreatic stent. Conventional 
transmural drainage can be performed without EUS guid-
ance when 1) gastric bulge/luminal impression by the cyst 
is present, 2) collateral blood vessels from portal hyperten-
sion are absent, and 3) the distance from the pseudocyst to 
the gastric/duodenal lumen on imaging studies is < 1 cm. 
For pseudocysts that are not amenable to such convention-
al endoscopic drainage, EUS-guided drainage has been 
shown to be equally successful, with no increased risk of 
complications [63]. Broad-spectrum antibiotic coverage 
by the intravenous route is given immediately prior to the 
endoscopic drainage procedure.
Technique of transmural drainage
The aim of direct cystenterostomy is to create a com-
munication between the cyst lumen and the gastric or 
duodenal lumen. The first step is to puncture the gut wall 
at the apex of the visible bulge (Fig. 3A and 3B) using a 
needle knife via a duodenoscope or, if EUS is indicated, a 
19-gauge fine needle aspiration (FNA) needle via a linear 
echoendoscope [64,65]. Once the puncture is achieved, a 
guide wire is advanced through the needle knife or FNA 
needle into the cyst cavity and looped 360° to secure posi-
tioning under fluoroscopic guidance (Fig. 3C). The newly 
created tract is then balloon dilated to 8-10 mm in size, 
or larger if necrotic material is present (Fig. 3D). This is 
usually followed by vigorous flow of pseudocyst fluid into 
the gut lumen, prior to which care should be taken to have 
aspiration precautions in place, with the head of the fluo-
roscopy table elevated and oropharyngeal suction. Two or 
more double pigtail stents are placed transmurally into 
the cyst cavity. Pre-assembled EUS-guided puncture kits 
are now commercially available to circumvent numer-
ous steps of cyst entry, exchange of guide wires, and stent 
placement. A nasocystic drain is placed in the presence 
of significant debris/necrosis or infection to allow for la-
vage of the cyst cavity. After drainage, the size of the cyst 
cavity is followed via ultrasound or CT scan at 4-6-week 
intervals to assess resolution. Once the cyst resolves, the 
transmural stents can be removed. If a pancreatogram had 
not been obtained and ductal disease treated at the initial 
endoscopic procedure, this should be done at the time of 
stent removal.
Results








Figure 3. Pancreatic pseudocyst drainage. (A) Visible bulge in the stomach. (B) Puncture of pseudocyst. (C) Wire in pseudocyst. (D) Di-
lation of cystogastrostomy tract. (E) Placement of transgastric stents. (F) Fluoroscopic image of transgastric stents.Tan Dmy and sherman s. Endoscopic therapy in chronic pancreatitis     393
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and the rate of successful resolution of the cyst was ap-
proximately 90% in pooled patients from multiple series 
[66]. In these series, the long-term recurrence rate was 
10-15%, and complications rates, primarily bleeding and 
perforation, were 10-34%. More recent studies [63,67,68] 
showed similar results with technical success > 90%, long-
term cyst and symptom resolution rates ranging from 71 to 
91%, and recurrence rates ranging from 16 to 18%. Baron 
et al. [69] reported that the rate of pseudocyst resolution 
was higher (92%) in patients with CP than in those with 
acute pancreatitis (74%), with comparable complication 
rates between the two groups (17% and 19%, respectively, 
p value not significant). These excellent results support the 
use of endoscopic drainage in appropriate patients, and 
the overall complication rates compare favorably to surgi-
cal interventions.
COEXISTING SPHINCTER OF ODDI DYS-
FUNCTION 
Pancreatic sphincter of Oddi dysfunction (SOD) can oc-
cur primarily or secondary to deposition of protein plugs 
on the sphincter and extension of scarring of the pancreas 
[70,71]. This results in pancreatic ductal obstruction and 
hypertension. Pancreatic SOD is suspected with worsen-
ing symptoms and/or dilated main PD without any other 
structural abnormalities. This condition can be evaluated 
and documented by pancreatic sphincter manometry. It 
is primarily treated by pancreatic sphincterotomy at the 
major papilla and placement of temporary pancreatic stent 
for prophylaxis against post-ERCP pancreatitis. Okolo et 
al. [72] reported that in 55 patients (40 with chronic pan-
creatitis) who underwent pancreatic sphincterotomy for 
manometrically documented pancreatic SOD, 60% had 
improved pain scores at a median follow-up of 16 months. 
In another study, Gabbrielli et al. [23] reported that 64% 
of CP patients with a dilated PD, of whom 45.5% (5 of 11) 
had no pancreatic stones or stricture, had absence of pain 
at a mean follow-up of 6.5 years with pancreatic sphinc-
terotomy alone. These data and our experience show that 
pancreatic sphincterotomy can be used as sole therapy in 
cases of documented pancreatic sphincter hypertension 
coexisting with CP. In our experience, we have found that 
at least 40% of patients with CP have associated sphincter 
of Oddi hypertension. However, it is unclear whether this 
contributes to CP or is the result of CP. There have been no 
reports regarding the outcomes of pancreatic sphincterot-
omy in patients with elevated sphincter of Oddi pressure in 
the setting of nondilated PD. We are currently conducting 
a prospective trial to study the outcomes of sphincterotomy 
in patients with pancreatic SOD with and without CP.
COEXISTING PANCREAS DIVISUM
Pancreas divisum is the most common congenital vari-
ant of pancreatic ductal anatomy and occurs when the dor-
sal and ventral PDs fail to fuse during the second month 
of gestation. With duct nonunion, the major portion of the 
pancreatic exocrine juice drains into the duodenum via 
the dorsal duct and minor papilla. It has been proposed 
that relative obstruction of pancreatic exocrine juice flow 
through the minor papilla could result in pancreatic-type 
abdominal pain, acute pancreatitis, or CP in a subpopula-
tion of pancreas divisum patients [73]. Endoscopic at-
tempts to decompress the dorsal duct in symptomatic 
pancreas divisum patients have been performed primarily 
by dilation, stent insertion, and/or minor papilla sphinc-
terotomy. The reported symptom improvement following 
endoscopic therapy for pancreas divisum in the setting of 
CP is much lower than for the recurrent acute pancreatitis. 
In 52 patients treated (11 with CP) by minor papilla sphinc-
terotomy, Lehman et al. [74] reported that 27% of the CP 
group benefited compared with 76.5% of the acute recur-
rent pancreatitis group followed up for periods between 6 
months and 1.5 years. A longer-term study (median follow-
up of 43 months) of 113 pancreas divisum patients (22 had 
CP) treated by minor papilla therapy was reported by Bo-
rak et al. [75]. Primary and secondary success rates for CP 
were 18.2% and 45.5% vs. 53.2% and 71% in the acute and 
recurrent pancreatitis groups, respectively.
These data show that minor papilla therapy of pancreas 
divisum patients with CP is less effective than the same 
therapy in patients with acute recurrent pancreatitis. How-
ever, endoscopic therapy can still be offered to patients 
with disabling symptoms. It should be appreciated that 
the endoscopic approach to ductal disease in patients with 
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ENDOTHERAPY ON ADJACENT STRUC-
TURES
Distal common bile duct stricture
Common bile duct stricture in CP can be malignant or 
from benign disease. It is important to exclude malignancy 
with a CT scan of the abdomen with pancreatic protocol 
and EUS with or without FNA prior to endoscopic treat-
ment if there is clinical suspicion. Once the biliary stric-
ture is determined to be benign, it is important to identify 
correctable causes, such as a pseudocyst causing extrinsic 
compression on the bile duct or pancreatic inflamma-
tion/edema in the setting of acute exacerbation of CP. 
The precise incidence of benign biliary strictures (BBSs) 
secondary to fibrosis and calcification within the pancre-
atic head is unknown and varies from 3 to 46% [76]. This 
type of BBS is irreversible without intervention and can 
result in jaundice, cholangitis, and progressive secondary 
biliary cirrhosis. Indications for biliary decompression in 
CP include symptoms (e.g., jaundice, cholangitis), biliary 
cirrhosis, common bile duct stones, progression of biliary 
stricture, and persistent asymptomatic elevation of alka-
line phosphatase and/or bilirubin for > 1 month (a thresh-
old twice the upper limit of normal values is often chosen 
for alkaline phosphatase) [77]. Hammel et al. [78] reported 
regression of hepatic fibrosis when the CBD was surgically 
drained. Although traditionally, BBSs in CP are treated by 
surgery with good long-term success, there is significant 
surgical morbidity in frequently debilitated patients with 
alcoholic CP and associated liver disease. Deviere et al. [79] 
were first to report the use of endoscopic treatment of the 
BBS in CP with endoscopic sphincterotomy, followed by 
insertion of one or two 10 Fr biliary stents with as-needed 
stent changes. Although technical success and short-term 
resolution of cholestasis and cholangitis was 100%, long-
term (mean, 14 months; range, 4 to 72) stricture resolution 
was much less satisfactory, occurring at a rate of 12%. An-
other study also indicated low stricture resolution rates of 
only 10-38% over a mean follow up of 18-58 months [25]. 
Subsequent studies involving serial placement of multiple 
simultaneous biliary stents to achieve gradual dilation of 
the BBS improved outcomes, with a long-term resolution 
rate of BBSs with multiple plastic stents ranging from 44 
to 92% over a 12 to 48-month follow-up period [80-82]. 
SEMSs (uncovered and partially covered) designed for 
permanent placement were evaluated for BBSs in the set-
ting of CP. Again, technical success and initial reversal of 
cholestasis and cholangitis were 100%, although at long-
term follow-up ranging from 22 to 50 months, the stents 
were occluded in 10-62% of cases. Stent patency rate 
dropped from 100% at 12 months to 40% at 24 months 
and 37.5% at 30 months [83-85]. In such patients, subse-
quent options are to refer for surgery or repeat endoscopic 
procedures for stent-in-stent placement. 
In an attempt to decrease the number of serial endo-
scopic procedures and avoid the disadvantage of clogged 
permanent stents. Kaheleh et al. [86] reported stricture 
resolution after a median stent interval of 4 months (range, 
1 to 28) with a partially covered metal stent and no recur-
rent symptoms during a 12-month (range, 3 to 26) follow-
up period after stent removal in 17 of 22 (77%) patients 
with CP. The same group had less success with fully cov-
ered stents. Eleven of 19 patients (58%) stented for a medi-
an of 3.3 months with a fully covered metal stent showed 
resolution of their stricture and no recurrent symptoms 
after stent removal during a 3.8-month follow-up period 
[87].
Briefly, in selected patients who are high-risk surgical 
candidates and those who wish to undergo endoscopic 
treatment for BBSs, endoscopic stenting with multiple 
plastic stents and/or self-expandable removable metal 
stents appears to be a potentially useful second-line thera-
py. However, more data on long-term outcomes, preferably 
in randomized trials in large numbers of patients, will be 
necessary before this therapy can be advocated as routine.
EUS-guided celiac plexus block/neurolysis
One of the mechanisms of pain related to CP is peripan-
creatic and celiac neuronal inflammation. There has been 
long-standing interest in decreasing neuronal inflamma-
tion with steroids and decreasing the perception of pain 
with anesthetic nerve block or neurolysis with alcohol. 
Neurolysis is usually reserved for malignant diseases 
because of concerns regarding the long-term effects of 
alcohol injection, including retroperitoneal fibrosis. Percu-
taneous (via lumbosacral muscles) or surgical approaches 
were used previously; however, transgastric EUS-guided 
celiac plexus block (EUS-CPB) has gained favor in the last 
decade due to the high success rate, lower complication 
rates, and simplicity of performing the procedure.Tan Dmy and sherman s. Endoscopic therapy in chronic pancreatitis     395
http://dx.doi.org/10.3904/kjim.2011.26.4.384 http://www.kjim.or.kr
Technique 
In this technique, a curvilinear array echoendoscope 
is used to identify the origin of the celiac trunk from the 
abdominal aorta. A recent report [88] also detailed the 
successful use of a prototype forward-viewing echoendo-
scope for performing celiac plexus neurolysis. The Mayo 
group showed that celiac ganglia can be directly visualized 
on EUS in 81% of patients [89] and that performing celiac 
ganglia block was technically feasible [90]. However, to 
date, there have been no studies comparing celiac ganglia 
block vs. celiac plexus block. Sakamoto et al. [91] recently 
showed that EUS-guided broad plexus neurolysis over the 
superior mesenteric artery using a 25-gauge needle gave 
better pain relief in pancreatic cancer patients than did 
conventional celiac plexus neurolysis. Whether this tech-
nique is applicable in cases of chronic pancreatitis using 
broad plexus block is still unknown.
   For celiac plexus or ganglia block, a 22- or 19-gauge EUS 
FNA needle is used for injection into the celiac region or, 
if feasible, directly in to the celiac ganglion. Once the FNA 
needle is advanced to the appropriate location, aspiration 
is first performed to make certain a vascular puncture 
has not occurred. Bupivacaine is first injected, followed 
by triamcinolone. Injection can be performed on one or 
both sides of the celiac trunk. In a prospective randomized 
trial, LeBlanc et al. [92] showed no difference in technical 
success, symptom response, or complication rates between 
one and two sites of injection during the same EUS-CPB 
session. Owing to the risk of hypotension, patients should 
be closely monitored for 2-4 hours after the procedure.
Results
In a retrospective series [93] and two prospective series 
[94,95], the overall success rate for EUS-CPB was 95%. 
The short-term pain improvement rate was 50-55%, and 
long-term pain relief at 12 weeks was 26%, whereas that 
at 24 weeks was 10%. Younger patients (< 45 years of age) 
and those with previous pancreatic surgery for CP were 
unlikely to have pain relief with EUS-CPB [94]. In a recent 
meta-analysis of 221 pooled patients from six studies, 
Kaufman et al. [96] found that the rate of short-term relief 
of abdominal pain from CP was 51.46%. Another meta-
analysis of 376 patients from nine studies conducted by 
Puli et al. [97], which included both celiac plexus block and 
neurolysis for chronic pancreatitis, showed 59.45% short-
term pain relief. Celiac ganglion injection under endosono-
graphic guidance yielded pain improvement in five of 13 
(38%) patients with CP when steroids were used vs. four 
of five (80%) patients receiving alcohol [90]. To date, there 
have been no studies comparing celiac plexus injection to 
sham controls [98], and there have been no head-to-head 
studies comparing neurolysis to nerve block in patients 
with chronic pancreatitis. Due to a lack of definite data, 
the relatively low response rates, and the requirement for 
repeat procedures, given the short duration of pain relief, 
EUS-CPB should be considered a temporizing measure 
reserved for cases in which oral analgesia is ineffective or 
in patients intolerant to medication side effects pending a 
more definitive intervention.
CONCLUSIONS
CP is a debilitating disease with pain as its major presen-
tation. The cause of pain is multifactorial and is thought to 
arise from several complications, such as ductal strictures, 
ductal stones, pseudocysts, and pancreatic cancer, which 
contribute to significant morbidity and mortality. A mul-
tidisciplinary approach on a case-by-case basis involving 
medical, endoscopic, and surgical management is the ideal 
approach for treatment of CP. Although two randomized 
studies have shown that surgical management is more du-
rable for the treatment of pain in a select group of patients 
with PD strictures/stones in the head and upstream dila-
tion, it may not always be a feasible option due to patient 
comorbidities or preferences. Endotherapy can be per-
formed with various combinations of pancreatic sphinc-
terotomy, stent placement, stricture dilation, ESWL, stone 
removal, pseudocyst drainage, and EUS-guided access and 
therapy. Endoscopic management has shown reasonable 
success in select patient populations, although the true 
rate of success is difficult to determine due to the retro-
spective nature of the majority of studies as well as to the 
variability in natural history and the multifactorial nature 
of pain in CP. Further randomized comparative controlled 
trials are warranted to define the role of endoscopic treat-
ment of CP. Further refinements in endoscopic equipment 
dedicated to the pancreas and advancements in technol-
ogy may help to improve the outcomes of endoscopic treat-
ment.396    The Korean Journal of Internal medicine Vol. 26, No. 4, December 2011
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